November 2nd, 2022: Massive Bio, a leader in AI-powered cancer clinical trial enrollment, has published the second issue of Massive Bio magazine. The publication, which had a successful debut in August, features a variety of content for cancer patients and their families, clinicians, and the business community. Featured content in
Massive Bio, a New York-based company with an AI tool that matches cancer patients with clinical trials appropriate to their cancer diagnosis, is planning bolt-on acquisitions following a Series B round likely to raise between USD 25m–USD 30m, co-founder and CEO Selin Kurnaz said. The health-tech company recently raised a
November 17th 2022: Massive Bio, which uses artificial intelligence to match cancer patients to clinical trials, launches “I Have Cancer,” a social media campaign to raise cancer awareness. In keeping with its mission to improve the lives of cancer patients, Massive Bio aims to raise mass awareness about cancer,